By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Addex Therapeutics 

12, Chemin Des Aulx
1228 Plan-les-Ouates
Geneva      Switzerland
Phone: 41-22-884-1555 Fax: 41-22-884-1556




Company News
Addex Therapeutics (ADXN.SW) Raises CHF2.8 million In A Private Placement And Extends Cash Runway Through 2017 3/9/2015 8:58:10 AM
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015 10:29:31 AM
Addex Therapeutics (ADXN.SW) mGluR2 NAM Demonstrates Protection In Preclinical Model Of Ischemic Neuronal Death 2/19/2015 11:17:08 AM
Addex Therapeutics (ADXN.SW) And Dystonia Medical Research Foundation Announce Partnership To Explore The Therapeutic Use Of Dipraglurant In The Treatment Of Dystonia 1/19/2015 10:45:14 AM
Addex Therapeutics (ADXN.SW) Completes 2014 With Strong Cash Position And Provides 2015 Strategic Update 1/9/2015 8:14:37 AM
Addex Therapeutics (ADXN.SW) And NIAAA Enter Collaboration To Evaluate ADX71441 In Alcohol Use Disorder 1/7/2015 9:36:44 AM
Addex Therapeutics (ADXN.SW) Amends mGlu2PAM Collaboration Agreement And Receives USD757,000 12/17/2014 9:43:18 AM
Addex Therapeutics (ADXN.SW) And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A Disorder 10/21/2014 9:13:25 AM
Addex Therapeutics (ADXN.SW) Reports First Half 2014 Financial Results 9/30/2014 9:01:48 AM
Addex Therapeutics (ADXN.SW) ADX71441 Positive Results In Preclinical Model Of Nicotine Addiction 7/10/2014 6:06:33 AM